Skip to main content
Figure 3 | Journal of Translational Medicine

Figure 3

From: Interleukin-13 receptor α2 DNA prime boost vaccine induces tumor immunity in murine tumor models

Figure 3

Therapeutic IL-13Rα2 DNA and boost vaccination inhibited established MCA304, 4T1, and D5α2 tumor growth. (A) Therapeutic vaccination schedule in tumor bearing mice. Palpable tumors were established in 3 to 5 days. Mice (n = 6 per group) were vaccinated as shown in Figure 3A. The ECDα2 boosted mice showed significant inhibition of tumor growth compared to IL-13Rα2 DNA vaccine alone in MCA304 (B), 4T1 (D) and D5α2 (F) tumor models. Kaplan-Meier survival curves of MCA304 (C), 4T1 (E) and D5α2 (G) tumor models were plotted. Ovalbumin, an irrelevant protein boost was used as a negative control. CpG in IFA served as negative control for ECDα2 protein. Experiments were repeated twice; bars, SD.

Back to article page